๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects

โœ Scribed by R. Grimaldi; E. Perucca; G. Ruberto; C. Gelmi; F. Trimarchi; M. Hollmann; A. Crema

Publisher
Springer
Year
1986
Tongue
English
Weight
250 KB
Volume
29
Category
Article
ISSN
0031-6970

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pharmacokinetics and pharmacodynamics of
Pharmacokinetics and pharmacodynamics of CI-992 following intravenous and oral administration to cynomolgus monkeys
โœ Jack A. Cook; Paula J. Burger; Barbara M. Michniewicz; Gerald D. Nordblom; Gary ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 163 KB ๐Ÿ‘ 1 views

The purpose of this study was to characterize CI-992 pharmacokinetics and pharmacokinetics/pharmacodynamics (PK/PD) in sodium deplete monkeys. Panels of monkeys were administered CI-992 as a 1 h intravenous infusions (0.1 and 1 mg kg -1 ) or as single oral doses (0, 10, 50, and 100 mg kg -1 ). Mean

Pharmacokinetics of dolasetron following
Pharmacokinetics of dolasetron following single- and multiple-dose intravenous administration to normal male subjects
โœ Ajit Shah; Robert Lanman; Vijay Bhargava; Scott Weir; William Hahne ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 561 KB

Dolasetron, AnzemetTM, a 5-hydroxytryptamine receptor antagonist, is under investigation as an antiemetic agent. The keto-reduced metabolite of dolasetron has been identified in human plasma and is probably responsible for the majority of the antiemetic activity. This study evaluated the pharmacokin